Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BNT116 · 1 trial · 1 indication
Proportion of patients with a best overall response of confirmed complete response (CR) or partial response (PR)
| Arm | Type | Description |
|---|---|---|
| Phase 2: Cemiplimab | EXPERIMENTAL | Arm A: Cemiplimab is administered by IV infusion Q3W |
| Phase 2: BNT116 + Cemiplimab | EXPERIMENTAL | Arm B: BNT116 is administered by IV injection. Cemiplimab is administered by IV infusion Q3W. |
| Name | Type | Description |
|---|---|---|
| BNT116 | DRUG | BNT116 is administered by IV injection. |
| Cemiplimab | DRUG | Cemiplimab is administered Q3W by IV infusion |
Key Inclusion Criteria 1. Participants with non-squamous or squamous histology NSCLC with stage IIIB or stage IIIC disease who are not candidates for surgical resection or definitive chemoradiation per investigator assessment or stage IV (metastatic) disease who received no prior systemic treatment...
Top 20 of 83 competitors
BNT116 is an investigational cancer vaccine being studied for the treatment of advanced non-small cell lung cancer. It is currently in Phase 2 clinical development and is being evaluated in combination with cemiplimab in adults with this condition.
BNT116 targets LAG-3, a protein involved in immune regulation. By targeting LAG-3, the vaccine aims to stimulate an immune response against cancer cells. It is being studied as a potential treatment for advanced non-small cell lung cancer.
BNT116 is being developed by Regeneron Pharmaceuticals, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol REGN. The company is conducting clinical trials to evaluate the vaccine's safety and efficacy in advanced non-small cell lung cancer.
BNT116 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials for the treatment of advanced non-small cell lung cancer.
BNT116 is being studied in a Phase 2 clinical trial with the identifier NCT05557591. This trial, known as EMPOWERVAX Lung 1, is evaluating the combination of BNT116 with cemiplimab in adults with advanced non-small cell lung cancer. The trial is active but not recruiting participants.
Yes, BNT116 is a cancer vaccine designed to treat advanced non-small cell lung cancer. It is being studied in combination with cemiplimab in a Phase 2 clinical trial. The vaccine targets LAG-3, a protein involved in immune response regulation.